Review



anti human bmp10 detection antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems anti human bmp10 detection antibody
    Anti Human Bmp10 Detection Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+bmp10+detection+antibody/Human+BMP-10+Propeptide+Biotinylated+Antibody/pm41222740-109-3-9
    Average 93 stars, based on 8 article reviews
    anti human bmp10 detection antibody - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    RNA Sequencing:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Isolation:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Recombinant:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Control:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Gene Expression:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Double Knockout:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Knock-Out:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Enzyme-linked Immunosorbent Assay:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Expressing:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Staining:

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity.
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.

    Article Title: BMP9 knockout impairs pulmonary vessel muscularisation and confers aberrant tamoxifen sensitivity
    Article Snippet: Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.Recombinant human BMP10 standards (4.88–5000 pg/ml) were prepared in the same final concentrations of additives.. After washing, biotinylated anti‐human BMP10 detection antibody (0.1 μg/well; R&D Systems) was added in PBS/1% BSA containing 0.2% GS.. After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.After further washing, Streptavidin-HRP (R&D Systems) was diluted in PBS/1% BSA according to the lot dilution stated by the manufacturer and then added.



    Similar Products

    93
    R&D Systems anti human bmp10 detection antibody
    Anti Human Bmp10 Detection Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+human+bmp10+detection+antibody/Human+BMP-10+Propeptide+Biotinylated+Antibody/pm41222740-109-3-9
    Average 93 stars, based on 1 article reviews
    anti human bmp10 detection antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results